CureMatch will analyze molecular profiles of US Special Operations Forces cancer patients and produce reports with treatment strategies.

NEW YORK – Radiopharm Theranostics on Tuesday said it was cleared by Australian regulators to begin a Phase I trial of its KLK3-targeting radiotherapeutic, RAD 402, for the treatment of metastatic or ...

The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.

They face a difficult choice, since the treatment may benefit their children but comes with serious risks and unknowns, particularly following reports of patient deaths.

The firm will use the funds to support clinical trials of its ATR inhibitor alnodesertib and its pol theta inhibitor ART6043.

The company plans to use the proceeds to test its TCR-T cell therapy in patients with MAGE-A4-positive solid tumors.

The recommendation is based on the Phase II/III DEVOTE study testing the higher dose in treatment-naïve patients and those already on the low dose.

The agency is cautioning patients about the risk of serious, possibly fatal, liver injuries and has limited the gene therapy's use to ambulatory patients.

Investigators at Boston institutions believe the regimen could target immunosuppressive lipid macrophages and improve ...

The agency reviewed data from a Phase II study, in which around 21 percent of patients had a complete response to the menin inhibitor.

Studies of germline genetic testing programs provide a snapshot of challenges at academic and community practices at the NSGC annual meeting.

NEW YORK – Fondazione Telethon said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for its gene therapy ...